Patents by Inventor Catherine Prades

Catherine Prades has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200399369
    Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Application
    Filed: April 8, 2020
    Publication date: December 24, 2020
    Inventors: Mangaiarkarasi ASOKAN, Christian BEIL, Jochen BENINGA, Joerg BIRKENFELD, Mark CONNORS, Richard A. KOUP, Young Do KWON, Peter D. KWONG, Qingbo LIU, Paolo LUSSO, John R. MASCOLA, Gary J. NABEL, Amarendra PEGU, Huawei QIU, Ercole RAO, Joerg REGULA, Edward SEUNG, Ronnie WEI, Lan WU, Zhen XING, Ling XU, Zhi-Yong YANG, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
  • Publication number: 20200317761
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Application
    Filed: March 13, 2020
    Publication date: October 8, 2020
    Inventors: Christian BEIL, William H. BRONDYK, Yangde CHEN, Seng H. CHENG, Timothy D. CONNORS, Catherine DEVAUD, Dietmar HOFFMANN, Christian LANGE, Maureen MAGNAY, Tristan MAGNAY, Catherine PRADES, Ercole RAO, Leila SEVIGNY, Ronnie WEI, Hongmei ZHAO, Yunxiang ZHU
  • Publication number: 20200140552
    Abstract: The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.
    Type: Application
    Filed: October 8, 2019
    Publication date: May 7, 2020
    Inventors: Lan WU, Ling XU, Edward SEUNG, Ronnie WEI, Gary NABEL, Zhi-Yong YANG, Tarik DABDOUBI, Béatrice CAMERON, Cendrine LEMOINE, Catherine PRADES
  • Patent number: 10626169
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: April 21, 2020
    Assignee: Sanofi
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • Publication number: 20190106504
    Abstract: The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 11, 2019
    Inventors: Lan WU, Ling XU, Edward SEUNG, Ronnie WEI, Gary NABEL, Zhi-Yong YANG, Tarik DABDOUBI, Béatrice CAMERON, Cendrine LEMOINE, Catherine PRADES
  • Publication number: 20180237511
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Application
    Filed: February 16, 2018
    Publication date: August 23, 2018
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • Patent number: 9493529
    Abstract: The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also relates to a composition including such a recombinant protein. Another aspect of the invention involves using a Robo1-Fc molecule as a diagnostic tool for detecting the overexpression of a molecule belonging to the Slit family in a patient.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: November 15, 2016
    Assignee: Sanofi
    Inventors: Francis Blanche, Beatrice Cameron, Tarik Dabdoubi, Frederique Dol-Gleizes, Pierre Fons, Catherine Prades, Jean-Pascal Herault
  • Publication number: 20130039912
    Abstract: The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also relates to a composition including such a recombinant Another aspect of the invention involves using a Robo1-Fc molecule as a diagnostic tool for detecting the overexpression of a molecule belonging to the Slit family in a patient.
    Type: Application
    Filed: April 8, 2011
    Publication date: February 14, 2013
    Applicant: SANOFI
    Inventors: Francis Blanche, Beatrice Cameron, Tarik Dabdoubi, Frederique Dol-Gleizes, Pierre Fons, Catherine Prades, Jean-Pascal Herault
  • Patent number: 8273548
    Abstract: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: September 25, 2012
    Assignee: Aventis Pharma S.A.
    Inventors: Han Koutnikova, Alexis Brice, Alain Fournier, Laurent Pradier, Catherine Prades, Isabelle Arnould-Reguigne, Marie-Françoise Rosier-Montus, Olga Corti
  • Patent number: 7378274
    Abstract: The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis. The invention also relates to nucleotide constructs comprising a polynucleotide which encodes a polypeptide or a nucleic acid of interest, placed under the control a regulatory nucleic acid for the ABC1 gene. The invention also relates to recombinant vectors, transformed host cells and nonhuman transgenic mammals comprising a nucleic acid which regulates the transcription of the ABC1 gene or an abovementioned nucleotide construct, as well as methods for screening molecules or substances which are capable of modifying the activity of the regulatory nucleic acid for the ABC1 gene.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: May 27, 2008
    Assignee: Aventis Pharma S.A.
    Inventors: Marie-Françoise Rosier-Montus, Catherine Prades, Cendrine Lemoine, Laurent Naudin, Patrice Denefle, Nicolas Duverger, Bryan Brewer, Alan Remaley, Sylvia Santamarina-Fojo
  • Publication number: 20060287230
    Abstract: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
    Type: Application
    Filed: March 28, 2006
    Publication date: December 21, 2006
    Inventors: Hana Koutnikova, Alexis Brice, Alain Fournier, Laurent Pradier, Catherine Prades, Isabelle Arnould-Reguigne, Marie-Francoise Rosier-Montus, Olga Corti
  • Patent number: 7132396
    Abstract: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: November 7, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Hana Koutnikova, Alexis Brice, Alain Fournier, Laurent Pradier, Catherine Prades, Isabelle Arnould-Reguigne, Marie-Françoise Rosier-Montus, Olga Corti
  • Publication number: 20060063166
    Abstract: The present invention relates to a novel human ABCC12 gene as well as the cDNAs encoding the novel short and long of ABCC12 proteins isoforms. The invention also relates to vectors and recombinant host cells comprising such nucleic acids, nucleotide probes and primers, and means for the detection of polymorphisms and mutations in the ABCC12 gene or in the corresponding proteins isoforms produced by the allelic form of the ABCC12 gene.
    Type: Application
    Filed: December 16, 2004
    Publication date: March 23, 2006
    Applicant: Aventis Pharma S. A.
    Inventors: Marie Rosier, Catherine Prades, Isabelle Arnould, Michael Dean, Rando Allikmets, Patrice Denefle
  • Publication number: 20050158784
    Abstract: The present invention relates to nucleic acids corresponding to various exons of the ABCC11 gene as well as the cDNA encoding the novel full length of ABCC11 protein. The invention also relates to means for the detection of polymorphisms in general, and of mutations in particular, in the ABCC11 gene or in the corresponding protein produced by the allelic form of the ABCC11 gene.
    Type: Application
    Filed: January 12, 2005
    Publication date: July 21, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Marie Rosier, Catherine Prades, Isabelle Arnould, Michael Dean, Rando Allikmets, Patrice Denefle
  • Patent number: 6893841
    Abstract: The present invention relates to nucleic acids corresponding to various exons of the ABCC11 gene as well as the cDNA encoding the novel full length of ABCC11 protein. The invention also relates to means for the detection of polymorphisms in general, and of mutations in particular, in the ABCC11 gene or in the corresponding protein produced by the allelic form of the ABCC11 gene.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: May 17, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Marie Rosier, Catherine Prades, Isabelle Arnould, Michael Dean, Rando Allikmets, Patrice Denefle
  • Publication number: 20040185456
    Abstract: The invention relates to nucleic acids corresponding to different exons and introns of gene ABC1 which is shown to be a gene causing pathologies linked to cholesterol metabolism dysfunction causing diseases such as atherosclerosis, more particularly perturbation of reverse cholesterol transport and more particularly the FHD's such as Tangier Disease
    Type: Application
    Filed: June 18, 2003
    Publication date: September 23, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Patrice Denefle, Marie-Francoise Rosier-Montus, Isabelle Arnould-Reguigne, Catherine Prades, Laurent Naudin, Cendrine Lemoine, Nicolas Duverger, Stephan Rust, Gerd Assmann, Harald Funke, H. Bryan Brewer
  • Publication number: 20030087246
    Abstract: The present invention relates to a novel human ABCA12 gene as well as cDNAs encoding the novel full and short length ABCA12 proteins. The invention also relates to vectors and recombinants host cells comprising such nucleic acids, nucleotide probes and primers, and means for the detection of polymorphisms and mutations in the ABCA12 gene or in the corresponding protein produced by the allelic form of the ABCA12 gene.
    Type: Application
    Filed: February 12, 2002
    Publication date: May 8, 2003
    Inventors: Isabelle Arnould-Reguigne, Catherine Prades, Laurent Naudin, Cendrine Lemoine, Michael Dean, Patrice Denefle, Marie-Francoise Rosier-Montus
  • Publication number: 20030077605
    Abstract: The present invention relates to a novel human ABCC12 gene as well as the cDNAs encoding the novel short and long of ABCC12 proteins isoforms. The invention also relates to vectors and recombinant host cells comprising such nucleic acids, nucleotide probes and primers, and means for the detection of polymorphisms and mutations in the ABCC12 gene or in the corresponding proteins isoforms produced by the allelic form of the ABCC12 gene.
    Type: Application
    Filed: March 5, 2002
    Publication date: April 24, 2003
    Inventors: Marie Rosier, Catherine Prades, Isabelle Arnould, Michael Dean, Rando Allikmets, Patrice Denefle
  • Publication number: 20030077591
    Abstract: The present invention relates to nucleic acid sequences that regulate the transcription of the ABCA7 gene, which may be involved in the metabolism of lipids in hematopoietic tissues, as well as in cell signaling mechanisms linked to the immune reaction and to inflammation. The invention also relates to polypeptides and polynucleotides that may be involved in diseases associated with the genetic locus q13 of chromosome 19.
    Type: Application
    Filed: October 24, 2001
    Publication date: April 24, 2003
    Inventors: Patrice Denefle, Marie-Francoise Rosier-Montus, Catherine Prades, Isabelle Arnould-Reguigne, Jose Osorio Y Fortea, Nicolas Duverger, Giovanna Chimini
  • Publication number: 20030059793
    Abstract: The present invention relates to nucleic acids corresponding to various exons of the ABCC11 gene as well as the cDNA encoding the novel full length of ABCC11 protein. The invention also relates to means for the detection of polymorphisms in general, and of mutations in particular, in the ABCC11 gene or in the corresponding protein produced by the allelic form of the ABCC11 gene.
    Type: Application
    Filed: March 5, 2002
    Publication date: March 27, 2003
    Inventors: Marie Rosier, Catherine Prades, Isabelle Arnould, Michael Dean, Rando Allikmets, Patrice Denefle